checkAd

    Ihr wollt die neue Rakete?? Hier ist sie.... - 500 Beiträge pro Seite

    eröffnet am 24.08.01 18:31:22 von
    neuester Beitrag 24.10.01 15:18:40 von
    Beiträge: 27
    ID: 461.228
    Aufrufe heute: 0
    Gesamt: 2.201
    Aktive User: 0


     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 24.08.01 18:31:22
      Beitrag Nr. 1 ()
      Aastrom/905286 (biotech)



      Ich glaube der Chart spricht für sich....ein Rebound unter dieser Marktstärke ist mehr als möglich ... unumgänglich!


      Alex2210
      Avatar
      schrieb am 24.08.01 18:34:40
      Beitrag Nr. 2 ()
      HA HA HA:laugh:

      SÒ EIN MIST:laugh:


      STRONG SELL:D:D
      Avatar
      schrieb am 24.08.01 18:35:51
      Beitrag Nr. 3 ()
      @scarface10: :laugh: ....du hast grad bewiesen das du keine Ahnung hast...!!!

      Alex2210
      Avatar
      schrieb am 24.08.01 18:37:17
      Beitrag Nr. 4 ()
      Es sei denn du kannst deine Aussage fundiert begründen!!

      Alex2210
      Avatar
      schrieb am 24.08.01 18:38:03
      Beitrag Nr. 5 ()
      ALEX:D
      `DU BLÖDER PUSHER:laugh::laugh:


      BIOS STRONG SELL:D

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 24.08.01 18:38:07
      Beitrag Nr. 6 ()
      Als Fehlstart müsste die aber noch weiter runter, die Bodenberührung muss noch sein.
      Avatar
      schrieb am 24.08.01 18:39:48
      Beitrag Nr. 7 ()
      Bodenberührung ist heut Nachmittag schon geschehen...Mit Erfolg...13% Rebound vom Tagestief!
      @Scarface: :laugh::laugh:
      Avatar
      schrieb am 24.08.01 18:48:30
      Beitrag Nr. 8 ()
      Keine weiteren Meinungen??

      Alex2210

      PS:Wer von euch ist investiert??
      Avatar
      schrieb am 24.08.01 18:50:48
      Beitrag Nr. 9 ()
      ALEX:D
      ICH SAGTE DOCH SCHON STRONG SELL!!!!!!

      :D:D
      Avatar
      schrieb am 24.08.01 19:16:45
      Beitrag Nr. 10 ()
      Tolle Beiträge hier!
      Halte 550 Stück! Ist zwar nicht viel! Steige weiter ein bei 1€! Die Stimmung ist zur Zeit nicht die beste! Denke aber dass sich Asstrom die nächsten 10 Jahre positiv entwickelt und auf 10 Jahressicht sind 10-15€ locker drin! Rate auch Stemcells (889118) mit ins Depot zu nehmen! Die stehen noch besser da. Übrigens soll das kein Gepush sein!

      Gruß
      Sugar
      Avatar
      schrieb am 25.08.01 10:43:07
      Beitrag Nr. 11 ()
      sehe auch positiv Stammzellen sind zwar umstritten aber es werden spektakuläre Meldungen kommen, so wie etwas heute mit der Herzinfarkt Heilung in wenigen Wochen... Stammzellen sind WUNDERMITTEL und es muß nicht immer embryonal sein (Nabelblut Knochenmark ...)


      Einfach liegenlassen, so wie ich mit 2ooo Stück in 1 Jahr rechne ich mit 5oo % PLUS in 5 Jahren mit 3ooo %

      bin als Apotheker vom Fach jede Menge MS Patienten, die mit Stammzellen geheilt werden können zur Zeit Interferon Therapie 25.ooo DM pro Jahr Medikamentenkosten Rebif z.B.

      also einfach abwarten wie bei Stemcell und Select Ther.

      So bald NEWS kommen, geht die Post ab

      drk
      Avatar
      schrieb am 06.09.01 15:06:18
      Beitrag Nr. 12 ()
      Aastrom Biosciences Receives Patent Covering an Integrated System For Producing Human Cells
      9/6/01

      - Proprietary Coverage Expanded for AastromReplicell(TM) System -

      ANN ARBOR, Mich, Sep 6, 2001 /PRNewswire via COMTEX/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that it received from the U.S. Patent and Trademark Office patent number 6,238,908 entitled, "Apparatus and Method for Maintaining and Growing Biological Cells." This new patent provides coverage for an integrated system of instrumentation and the related methods for receiving, maintaining and growing human cells ex vivo within a portable cassette, without exposing the cells to the external environment. The new patent coverage expands earlier issued component and device claims, to provide more complete protection of the AastromReplicell(TM) System products and technology for growing high quality human cells intended for therapeutic uses.
      "We continue to build Aastrom`s patent portfolio to cover our biological processes, our devices and our clinical systems. While our stem cell production processes and each component of the AastromReplicell(TM) System are covered by separate patents, this new patent provides total integrated system coverage," said R. Douglas Armstrong, Ph.D., President and Chief Executive Officer of Aastrom. "The AastromReplicell(TM) System platform places Aastrom in a strategic industry position to commercialize cell therapies."

      Each new laboratory discovery using human stem and other cells expands

      @ ALEX 2210 nun fliegt die rakte doch noch ...den dummschwätzern ein schönes zusehen.
      grüße t.1
      Avatar
      schrieb am 06.09.01 15:35:11
      Beitrag Nr. 13 ()
      Hallo ASTMler





      Aastrom Biosciences Receives Patent Covering an Integrated System For Producing Human Cells
      THURSDAY, SEPTEMBER 06, 2001 8:00 AM
      - PRNewswire

      ANN ARBOR, Mich, Sep 6, 2001 /PRNewswire via COMTEX/ -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) announced today that it received from the U.S. Patent and Trademark Office patent number 6,238,908 entitled, "Apparatus and Method for Maintaining and Growing Biological Cells." This new patent provides coverage for an integrated system of instrumentation and the related methods for receiving, maintaining and growing human cells ex vivo within a portable cassette, without exposing the cells to the external environment. The new patent coverage expands earlier issued component and device claims, to provide more complete protection of the AastromReplicell(TM) System products and technology for growing high quality human cells intended for therapeutic uses.

      "We continue to build Aastrom`s patent portfolio to cover our biological processes, our devices and our clinical systems. While our stem cell production processes and each component of the AastromReplicell(TM) System are covered by separate patents, this new patent provides total integrated system coverage," said R. Douglas Armstrong, Ph.D., President and Chief Executive Officer of Aastrom. "The AastromReplicell(TM) System platform places Aastrom in a strategic industry position to commercialize cell therapies."

      Each new laboratory discovery using human stem and other cells expands the range of clinical potential in the treatment of cancers, diseases and other disorders. One of the most limiting factors for these novel cell therapies is a means for moving cell production out of the research laboratory and into general medical practice. The AastromReplicell(TM) System is intended to broaden the practical utility of new cell therapies by enabling standardized ex vivo production of robust human cells in an automated, GMP-compliant system.

      Aastrom is a leader in the development of proprietary cell therapeutic products based on its dual-technology platforms: patented "single-pass perfusion" providing cells with enhanced biological function, and patented GMP-compliant system automation facilitating the delivery of cells for therapeutic use into medical practice. These technologies are integrated into the AastromReplicell(TM) System that is designed to uniquely standardize and automate the processes involved in producing high quality therapeutic cells. Aastrom is developing a range of cell therapeutic products including, the Dendricell(TM) products for use in the dendritic cell-based cancer vaccine market, and the OC-I bone progenitor cell product for the treatment of degenerative bone diseases such as osteoporosis. The AastromReplicell(TM) System, the SC-I bone marrow stem cell product and the CB-I cord blood cell product have received CE Mark approval necessary for European marketing and are in late-stage U.S. clinical trials. These products are not available for sale at this time in the U.S., except for research or investigational use.

      Please visit the Aastrom Biosciences website at http://www.aastrom.com
      This document contains forward-looking statements, including without limitation, statements regarding intended capabilities provided by Aastrom`s technologies and products under development, anticipated protection provided by issued patents, and potential advantages and applications of the AastromReplicell(TM) System, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the word "intend," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the availability of resources, the results obtained from clinical trial and development activities, uncertainties related to intellectual property protection, and regulatory approval requirements. These and other significant factors are discussed in greater detail in Aastrom`s Annual Report on Form- 10K, and other filings with the Securities and Exchange Commission.

      Bis dann Donkosak-Grischka:kiss:
      Avatar
      schrieb am 07.09.01 14:06:05
      Beitrag Nr. 14 ()
      donkosak

      Danke!!!
      Avatar
      schrieb am 07.09.01 16:25:39
      Beitrag Nr. 15 ()
      Hallo,
      Aastrom...Stammzellenforschung ist die Zukunft in der Biotechnologie!!!
      Doch im moment wird die Forschung nicht sehr viel unterstützt,was aber nicht unbedingt ein Nachteil heissen muss (Langfristig ist sie ein Goldader).

      In 5 Jahren werden wir(wenn überhaupt) sehen und uns darüber sehr ärgern das wir nicht Investiert haben!!!

      Ich zumindestens, werde in allen Stamzellenaktien Einkaufen.

      Meine favoriten:
      Stemcells
      Geron
      Aastrom
      Nexell
      Lifecell
      Select Therapeutics
      Haemonetics
      und Curis

      Sehr gute aussichten haben Stemcells, Curis,Geron,und vor allem noch Select Therapeutics!!!

      Aastrom würde ich noch etwas warten aber auf jedenfall spätestens Anfang nächstes Jahr kaufen!!

      Bye all :)
      Enes1
      Avatar
      schrieb am 09.09.01 17:56:44
      Beitrag Nr. 16 ()
      Zu ASTM:
      Bin selbst als Arzt tätig und aus der täglichen Praxis (Kardiologie)mit der Thematik vertraut. Man sollte bei diesen Werten einsteigen,denn der Zeitpunkt ist sicher günstig.Danach wirklich "Ruhe bewahren" und abwarten.
      Das Produkt der Firma taugt was!! Weitere Entwicklungen werden folgen und der grosse Durchbruch kommt. Aber es kann wirklich noch sehr lange dauern. Der Wert ist absolut nichts für Zocker.
      Avatar
      schrieb am 09.09.01 20:36:41
      Beitrag Nr. 17 ()
      Das Problem wird nur sein, dass von diesen Klitschen die meisten in fünf Jahren nicht mehr existieren. Liquidität ist schnell verbraucht und Kapitalerhöhungen sind bei Unternehmen, die nichts verdienen um umsetzen am Markt kaum durchzusetzen. PE-Investoren sind nach einem IPO auch nicht mehr zu gewinnen. Die Branche ist sicher richtig, das stockpicking aber extrem schwierig. Ich würde lieber auf die Marktführer oder einen Branchenfonds setzen.
      Avatar
      schrieb am 09.09.01 23:11:25
      Beitrag Nr. 18 ()
      @ENES

      woher beziehst Du Deine Informationen, wonach gerade Stemcells, Curis, Geron und vor allem Select Therapeutics die besten Aussichten haben sollen?
      Sind die finanziell abgesichert?

      Gruss

      Softliner
      Avatar
      schrieb am 17.09.01 15:04:10
      Beitrag Nr. 19 ()
      jetzt gehts wieder up Richtung 6
      Avatar
      schrieb am 27.09.01 17:29:28
      Beitrag Nr. 20 ()
      Keiner mehr so recht Lust zum Schreiben,oder?:confused:

      Million Worth Of Common Stock



      ANN ARBOR, Mich., Sept. 27 /PRNewswire/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that it has completed the public offering of 7,700,000 shares of common stock. These shares were sold in a series of transactions pursuant to a shelf registration statement. The shares were sold by Aastrom at prices ranging from $ 0.82 to $ 1.78 and resulted in aggregate gross proceeds to Aastrom of approximately $ 11 million.

      A prospectus may be obtained from Aastrom`s Investor Relations Department at P.O. Box 376, Ann Arbor, Michigan 48106.

      Aastrom is a leader in the development of proprietary cell therapeutic products based on its dual-technology platforms: patented "single-pass perfusion" providing cells with enhanced biological function, and patented GMP-compliant system automation facilitating the delivery of cells for therapeutic use into medical practice. These technologies are integrated into the AastromReplicell(TM) System that is designed to uniquely standardize and automate the processes involved in producing high quality

      Bis denne Euer Donkosak :rolleyes:
      Avatar
      schrieb am 28.09.01 16:01:46
      Beitrag Nr. 21 ()
      @donkosak
      meldung von gestern hat AASTROM gut geholfen 20% nach oben ......mal sehen ob es weiterhift.
      grüße t.1
      Avatar
      schrieb am 01.10.01 18:28:02
      Beitrag Nr. 22 ()
      Heute - Aastrom: Positive Studienergebnisse mit Stammzellen

      Eine neue klinische Studie, veröffentlicht in ?Bone Marrow Transplantation?, demonstriert eine neue alternative Behandlungsmöglichkeit mit Hilfe von Stammzellen, welche durch das von Aastrom entwickelte Produkt AastromReplicell hergestellt wurden. Aastrom Biosciences neue ?SC-I Bone Marrow Cell? Therapie dürfte bald für tausende von Patienten, die sich einer Stammzellen-Transplantation unterziehen müssen, eine wirksame und weniger invasive Methode sein, um die therapeutischen Mengen an Stammzellen zu erhalten, die für eine Wiederherstellung wichtiger Blut- und Immunzellen benötigt werden. Die im August 2001 veröffentlichte klinische Studie zeigt den therapeutischen Wert der durch SC-I außerhalb des Körpers vermehrten Stammzellen zur Wiederherstellung der normalen Blut- und Immunzellenfunktion in Patienten nach einer Chemotherapie.

      Die an den Medizinischen Zentren der Hackensack Universität, der Loyola Universität und dem Texas Cancer Institute durchgeführte Studie, schloss 31 Patienten mit metastasierendem Brustkrebs ein, deren Blut- und Immunsystem durch eine vorangegangene Chemotherapie zerstört worden war. Der Versuch benötigte nur eine geringe Menge peripherer Blutzellen der Patienten, diese wurden dann mit Aastroms SC-I außerhalb des Körper vermehrt und den Patienten erneut verabreicht. Die Ergebnisse zeigten nun, dass die Kombination aus geringen Mengen peripherer Blutstammzellen mit ex vivo hergestellten SC-I Knochenmarkstammzellen gleiche Raten bei der Wiederherstellung von Blutzellen zur Folge hatten, wie die Gabe höherer Dosen von nativen peripheren Blutstammzellen. Die Prozedur hat den Vorteil, dass Patienten, deren Knochenmark nicht mehr in der Lage ist, ausreichend Zellen zu produzieren, trotzdem mit einer aussreichenden Menge versorgt werden können und damit über weitaus bessere Überlebenschancen verfügen
      Avatar
      schrieb am 02.10.01 14:37:30
      Beitrag Nr. 23 ()
      Super News !!! Aastrom Biosciences Announces CE Mark Approval For First Dendritic Cell Therapy Product in Europe
      - Dendritic Cell Vaccines Offer New Therapy Options for Cancer Patients -
      ANN ARBOR, Mich., Oct. 2 /PRNewswire/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM - news), today announced that it has obtained approval to affix the CE Mark to the DC-I Cell Therapy Kit for the ex vivo production of human dendritic cells, allowing the Company to market and sell the product in Europe. The DC-I product is used to produce Aastrom`s innovative proprietary dendritic cell product, the Dendricell(TM), that is intended to provide a base dendritic cell for a broad range of cancer vaccines being developed using cancer-associated antigens.

      The DC-I dendritic cell production product utilizes Aastrom`s patented single-pass perfusion methodology, for enhanced cell biology and outcome reliability in the production of clinical quantities of dendritic cells. Additionally, the DC-I dendritic cell product is produced in the AastromReplicell(TM) System platform, enabling the automated, process-controlled cell production of human dendritic cells in compliance with regulatory requirements for Good Manufacturing Practice (GMP).

      ``Dendritic cell vaccines are aggressively being explored in the European clinical community,`` commented Holger Beckmann, Managing Director of Zellera AG, Aastrom`s European subsidiary. ``In conjunction with the excellent biological activity of the Dendricell(TM), Aastrom`s DC-I product automation addresses a clear need for GMP-compliant dendritic cell production capability, aiding the customers in meeting requirements of European regulatory agencies.``

      This announcement follows earlier approvals received by Aastrom to affix the CE Mark to the AastromReplicell(TM) System instrumentation platform, and the SC-I bone marrow and CB-I cord blood cell production products used for stem cell therapies. These developments have helped Aastrom secure an industry-leading position using cells for therapeutic procedures.

      Earlier this year Aastrom announced the initiation of external clinical beta site evaluations of the DC-I dendritic cell product at the Barbara Ann Karmanos Cancer Institute at Wayne State University (Detroit, MI), Beth Israel Deaconess Medical Center (Boston, MA), the Universitatsklinikum Charite (Berlin, Germany), and the University of Gottingen (Gottingen, Germany). Successful validation of the DC-I cell product by external sites demonstrates that Aastrom`s process performance is transferable and reproducible by external laboratories, and is a part of Aastrom`s quality system requirement for CE Marking.

      ``This significant milestone broadens Aastrom`s product and market opportunities beyond our previous stem cell therapy focus,`` said R. Douglas Armstrong, Ph.D., President and Chief Executive Officer of Aastrom. ``Most experts recognize the therapeutic potential of dendritic cell vaccines, but have not had the technology needed to provide an accessible, biologically robust, dendritic cell supply. Aastrom is meeting this market need by applying its proprietary cell culture capabilities to produce novel cell therapeutics in a practical approach.``

      About Zellera AG

      Zellera AG is a wholly-owned subsidiary of Aastrom Biosciences, Inc., located in Berlin, Germany. Zellera serves as the sales and marketing operational base for Aastrom`s products in Europe.

      About Aastrom Biosciences, Inc.

      Aastrom (http://www.aastrom.com) is a leader in the development of proprietary cell therapeutic products based on its dual-technology platforms: patented ``single-pass perfusion`` providing cells with enhanced biological function, and patented GMP-compliant system automation facilitating the delivery of cells for therapeutic use into medical practice. These technologies are integrated into the AastromReplicell(TM) System that is designed to uniquely standardize and automate the processes involved in producing high quality therapeutic cells. Aastrom is developing a range of cell therapeutic products including, the Dendricell(TM) products for use in the dendritic cell-based cancer vaccine market, and the OC-I bone progenitor cell product for the treatment of degenerative bone diseases such as osteoporosis. The AastromReplicell(TM) System, the SC-I bone marrow and the CB-I cord blood cell production products have previously received CE Mark approval necessary for European marketing and are in late-stage U.S. clinical trials. These products are not available for sale at this time in the U.S., except for research or investigational use.

      This document contains forward-looking statements, including without limitation, statements regarding product development objectives, clinical trial results, potential product applications and potential advantages of the AastromReplicell(TM) System and related cell therapy kits, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words ``intend,`` ``potential,`` and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the results obtained from clinical trial and development activities, research activities being conducted by others, regulatory approval requirements, the availability of resources, competitive developments and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom`s Annual Report on Form-10K, and other filings with the Securities
      Avatar
      schrieb am 08.10.01 21:27:08
      Beitrag Nr. 24 ()
      Hallo Leute

      War im Urlaub für eine Woche, hört sich nicht schlecht an, werde das mal genau prüfen.Danke für die News.

      Bis dann Donkosak:lick:
      Avatar
      schrieb am 09.10.01 16:08:00
      Beitrag Nr. 25 ()
      http://www.ceocfointerviews.com/interviews/AastromBio.htm

      Interview mit CEO Amstrong.
      Für alle die es noch interessiert!

      R. Douglas Armstrong, PhD
      President and
      Chief Executive Officer

      Interview conducted by:
      Walter Banks
      Co-Publisher

      CEOCFOinterviews.com
      July 2001

      BIO OF CEO
      R. Douglas Armstrong, Ph.D., has served as Aastrom Biosciences, Inc.`s President and Chief Executive Officer since 1991. In this capacity, Dr. Armstrong has been an integral part of the Company`s business development activities, including an inventor on the patents for the AastromReplicellä System. Additionally, he has led the efforts to raise more than $75 million in investment capital and has negotiated two major corporate partnerships. Dr. Armstrong was also elected as Chairman of Aastrom`s Board of Directors in 1999.

      Prior to joining Aastrom, Dr. Armstrong spent five years at The Burnham Institute, most recently as Executive Vice President, Trustee and Staff Scientist. Before joining The Burnham Institute, Dr. Armstrong served in various academic appointments at the University of Michigan, the University of California, San Francisco, and the Yale University School of Medicine.

      Dr. Armstrong received his Bachelor of Arts degree in Chemistry from the University of Richmond in Richmond, Virginia and completed his Doctorate in Pharmacology and Toxicology at the Medical College of Virginia. In addition, Dr. Armstrong serves on the Board of Directors of Cytomedix, Inc.

      About Aastrom Biosciences, Inc.

      Aastrom Biosciences, Inc., is a leader in the development of proprietary cell therapeutics and cell products based on the Company’s dual technology platforms: patented “single-pass perfusion” providing cells with enhanced biological function, and patented GMP-compliant system automation facilitating the delivery of cells for therapeutic use into medical practice. These technologies are integrated into the AastromReplicellTM System that is designed to uniquely standardize and automate the processes involved in producing robust, high quality therapeutic cells.

      The AastromReplicellTM System is a family of products designed to produce human cells outside of the body ("ex vivo") to enable a variety of medical procedures. Until now, growing human cells has been a research laboratory process, requiring substantial time and expertise. In contrast, the AastromReplicellTM System is designed to provide automated cell production capabilities directly at the patient care site.

      The AastromReplicellTM Cell Production System consists of a multi-use instrument platform intended to be sold to clinical care institutions, and a growing line of single-use cell therapy kits intended to be sold for each patient treatment. The AastromReplicellTM System is designed to enable the production of cells to replace or repair damaged human tissues or to treat infectious disease and cancer. Initially, Aastrom was known as a leading developer of stem cell therapeutics. Aastrom is now leveraging its core capabilities in the cancer and bone disease markets, as novel cell therapies emerge as possible medical treatments. Along these lines, Aastrom is developing the DC-I Cell Therapy Kit and the DendricellTM dendritic cell products for use in the rapidly growing cancer vaccine market, and the OC-I Cell Therapy Kit, a bone progenitor cell product for the treatment of degenerative bone diseases such as osteoporosis. The AastromReplicellTM System, the SC-I bone marrow stem cell product and the CB-I cord blood cell product have received CE Mark approval necessary for European marketing and are in late-stage U.S. clinical trials. These products are not available for sale at this time in the U.S., except for research and investigational use.

      CEOCFOinterviews - Dr. Armstrong, can you give us a brief history of Aastrom Biosciences?

      Dr. Armstrong: "Aastrom Biosciences is located in Ann Arbor, Michigan, because our lead technologies came out of a discovery at University of Michigan. Those discoveries involved methods and processes that enabled the growth of primary human cells. The Company took those base discoveries and went to work on two things. One, we wanted to learn how to grow these primary human tissues better, and secondly, we had to figure out how to make a business out of this capability. For this we went to work on developing a very novel platform that enables us to produce many types of primary human cells for therapeutic use. So, about ten years ago the Company began with the basic discovery of being able to grow human cells, and this year our tenth anniversary will be marked by bringing these cell products into the commercial market place in Europe."

      CEOCFOinterviews - What would you say is the most exciting news about Aastrom Biosciences at this point?

      Dr. Armstrong: "I think the excitement comes in two areas. One is in the field of dendritic cell tumor vaccines, for the treatment of cancer, which is rapidly becoming a reality. These new approaches require a type of human cell called a dendritic cell, which need to be produced and modified outside of the body to make the vaccine. Dendritic cells can be tailored to treat different forms of cancer. Aastrom is very aggressively moving into this field with the DendricellTM products. This is a new and growing opportunity for the Company, and naturally a very exciting time for medicine.

      The second area of excitement is more generic to the industry as a whole. There is a proliferation of cell-based therapeutic discoveries, and with discoveries come opportunities. These discoveries are being developed by different research groups, each learning how to use different types of human cells to treat specific diseases. What becomes important is how to move these discoveries out of the laboratory, and into a format that can be used in standard medical treatment. Aastrom has designed the AastromReplicellTM System to provide a commercialization pathway to move these discoveries into general medical practice."

      CEOCFOinterviews - Where exactly are you in dendritic cell cancer research and when can we expect a product on the market?

      Dr. Armstrong: "We see three different market opportunities for the dendritic cell. First, there are a variety of clinical trials ongoing today, and more being proposed, to test different dendritic cell-based vaccine approaches. Therefore, our business plan is to have these different clinical research groups utilize the Aastrom DendricellTM in creating these new approaches. This offers Aastrom a research-level market opportunity. We plan to begin sell our lead DendricellTM product in the clinical research marketplace beginning this Fall. That is a very near term market. The next phase of market opportunity begins when clinical trials are completed and the therapies move into regulatory approval. There is a large market growth potential for Aastrom when vaccines that use our cells move into general medical practice, building a more traditional pharmaceutical-type market for us. Another market opportunity we are aiming for is developing our own line of proprietary vaccines using different tumor antigens, which is a natural progression since Aastrom already has the novel base dendritic cell for producing these vaccines. This market has the potential to be a long-term revenue producer for us, and right now we are looking at a 3 to 6 year program. So, in summary we see first, the immediate research market opportunity; second, we see possibilities with some of the generic vaccines that come out of research and move into clinical use, and then, ultimately the very specific proprietary vaccines, all based on the DendricellTM.”

      CEOCFOinterviews - What type of revenue possibilities is there in this market?

      Dr. Armstrong: "Let me give you an example. We, recently established relationships with two research centers in Germany, one in Berlin and the other in G`ttingen. Both of these centers are currently involved in some fairly large clinical programs with cancer vaccines. They are currently evaluating the DendricellTM, and if the evaluations go well, they plan to utilize Aastrom’s DendricellTM in further vaccine development. These centers are already producing approximately ten vaccines a week. Each use of our dendritic cell product costs about $4,000 (although we have not yet determined final pricing). Thus, just using this model as an example, the production of approximately 500 vaccines a year times $4,000 becomes a material market for Aastrom."

      CEOCFOinterviews - How close to commercialization are you with the near term products you are working with?

      Dr. Armstrong: "Our main area of focus has been in bone marrow stem cell transplantation. Our lead product, the SC-I bone marrow cell therapy product, is designed to start with a very small amount of bone marrow and expand that into a large enough unit for a complete bone marrow transplant. We have been active clinically in the United States in trials using small amounts of bone marrow for cancer patients who cannot obtain sufficient stem cells through other sources. This is expected to be a niche market opportunity for us in near term. We have received CE Mark approval in Europe and next quarter shall begin to sell the SC-I stem cell product. We have also been moving forward with cord blood cells, which is a very exciting area. Cord blood cells are used to treat leukemia patients by being able to generate a normal blood and immune system following aggressive radiation or chemotherapy. Our CB-I cord blood product is also in Phase III trials in the United States and has been recently approved for sale in Europe."

      CEOCFOinterviews - Which of those two is the biggest market for you?
      Dr. Armstrong: "We think cord blood will emerge as the largest market because it really offers a transplant opportunity for the 30 to 50 thousand leukemia and blood disease patients who need a donor transplant to replace their diseased blood, but are unable to find a bone marrow match. Cord blood transplants are a new area, and will take some time for the clinical marketplace to generate confidence in the use of this product. These transplants represent a potential 250 million dollar market opportunity."
      CEOCFOinterviews - How much of the cord blood market do you think you can capture?
      Dr. Armstrong: "That depends on how deeply the market is penetrated, which will be driven by clinical results that are published and how those results affect the general market interest. Some of these studies are active right now and articles should be published in the coming year.

      In addition to the leukemia market, we have recently moved into the bone disease area. This reflects the versatility of the platform capability we have to produce specific cell types for the treatment of different diseases. We recently started a Phase I/II clinical trial at the University of Michigan for the treatment of severe osteoporosis. This involves taking a small amount of the patient`s own cells, and then using our OC-I cell therapy product, producing a large amount of bone forming progenitor cells, which are given back to the patient in hopes of remodeling or reconstructing their depleted bone. The bone and cartilage area is an important new focus for the company."

      CEOCFOinterviews - Where do the cells that you work with originate?
      Dr. Armstrong: "For many of the applications, the hospital takes a small amount of cells from the patients themselves. The cells may be taken from the blood, for example for dendritic cells, or from the hip, for a small bone marrow sample. The small cell sample is collected during a short outpatient procedure, and cells for transplantation are produced outside of the body. However, there are some applications, where the cells come from a donor. Cord blood, for example, is a banked and stored cell donation from the umbilical cord of an infant’s afterbirth. Aastrom’s cell therapeutics are produced using both patient- and donor-derived starting cell samples."
      CEOCFOinterviews - As a visionary, which area is the real future of your company?
      Dr. Armstrong: "I believe that the future of the company comes from the generic opportunity of using cells to treat diseases. The future is driven by the fact that we have more and more opportunities to use cells in the treatment of different types of diseases. Right now, we are looking at dendritic cells for tumor vaccines. We are looking at other cells to replace damaged blood and immune systems. We are looking at using cells to regenerate new bone tissue. I also think there will be new cell therapies to regenerate nerves, cardiac tissues and muscle. All of these possibilities require the ability to grow and produce cells to become therapeutic agents, and this is what Aastrom does. We are in a unique industry position to be on the brink of these discoveries, and to convert them into standard use clinical products."
      CEOCFOinterviews - Do you have any competition?
      Dr. Armstrong: "The competition that we have at the moment comes in the individual fields. There are different approaches being taken to treat different diseases, for example, if new drugs could be developed to eliminate leukemia, then there would be no need for cord blood transplants in leukemia patients. However, the ability to actually grow and produce cells today on a broad scale basis is unique to Aastrom Biosciences."
      CEOCFOinterviews - What is your patent position?
      Dr. Armstrong: "Great question, since this could be a pretty complicated area. Our patents go across three fields. First, there is the biology field where we have patents that cover our processes and approaches for growing primary human cells. For example, we have been issued a patent for the ex vivo production of human stem cells from bone marrow, cord blood and other blood-derived cells. Secondly, the methods we developed to grow and produce cells require something that we call single pass perfusion. To implement these processes we developed proprietary devices, or culture chambers, for growing cells. The third area we have covered by patents is our system automation, that allows us to completely automate the cell culture process. Thus, we have a family of patents around our system automation capability for the production of human therapeutic cells."
      CEOCFOinterviews - Where are you in the FDA approval process for cell replication?
      Dr. Armstrong: "We have two active Phase III clinical trials plus one completed trial which we are in discussion with the FDA now to potentially move forward with a PMA application.”
      CEOCFOinterviews - How are you approaching commercialization?

      Dr. Armstrong: "This past January we hired our first Vice President Market Operations, Audrey Hutter. Audrey comes from the medical device world as well as the pharmaceutical industry, and has a strong background in the marketing of the medical products. She is constructing our market operation strategy to move our products into the commercial marketplace. We have established an infrastructure to be able to import our product into Europe, and we are beginning to have some customer marketing activities there as well. Part of our plan for the coming year will be to establish full time ground support in Europe. We had announced a while back that we had formed a wholly-owned subsidiary company in Germany, called Zellera AG, which is now activated to handle the business activity for us in Europe. There are major clinical centers involved in therapeutic procedures. They are very identifiable, and can be reached with a relatively small marketing force. The majority of the market is actually captured in the minority of the clinical centers, and we do believe that we can market effectively and support the market ourselves without major partnerships."

      CEOCFOinterviews - What is your burn rate and your cash and credit position?

      Dr. Armstrong: "At the end of March the company had about 8.5 million dollars on the books, and we have been spending over the last year at a rate of about $400,000 dollars a month. Our burn rate has been pretty small, compared to other companies. Much of the decrease in the burn rate resulted from the completion of the product platform. Therefore, all of our activity in-house is now focused on new applications, using primary human cells to develop therapeutic approaches, and then moving these cell therapies into medical practice. Yet, we will be increasing our burn rate as we begin to move into the marketplace, using the capital to build product, moving it to Europe and to hire people to build the marketing effort. We also hope to see an increase in our revenue to offset our increased expenses.”

      CEOCFOinterviews – What final thoughts would you like to leave with your current shareholders and potential investors?

      Dr. Armstrong: "What I see as most important is that Aastrom has been here for ten years, and has evolved to be in a very unique situation of moving new cell therapy procedures into the medical marketplace."


      ceocfointerviews.com does not purchase or make
      recommendation on stocks based on the interviews published.

      .
      Avatar
      schrieb am 19.10.01 21:07:55
      Beitrag Nr. 26 ()
      Produkte
      AastromReplicell?-System-Instrumentenausrüstung Plattform Labors des Krankenhauses cell/blood, Zelle, die Service-Mitten verarbeitet Phase III/Pivotal, die in US prüft; CER-Markierung Zustimmung in Europa CER-Markierung Zustimmung in Europa
      Cb-iTherapieInstallationssatz
      (NetzkabelBlut) Leukämie und genetische Blutkrankheiten FDA genehmigte Protokoll für Studie der Phase III/Pivotal;
      Sc-iTherapieInstallationssatz
      (Knochenmark-Stammzellen) Feste Krebse Phase III/Pivotal; Zustimmung CERMmark in Europa
      Oc-iTherapieInstallationssatz
      (Zellen KnochenProgenitor) Strenges Osteoporosis Durchführbarkeitsanalyse der Phase I/II
      Cb-iiTherapieInstallationssatz
      (NetzkabelBlut) Leukämie und genetische Blutkrankheiten Durchführbarkeitsanalyse der Phase I/II
      Dc-iTherapieInstallationssatz
      (Dendritic Zellen) Krebse und Viren Vor-klinisch
      T-CellTherapieInstallationssatz
      (T-Cells) Krebse und Viren Vor-klinisch

      das AastromReplicell-System wird bei zulassung in den usa ein kursfeuerwerk auslösen,in europa ist das system schon auf dem markt (september 2001).der kurs ist ein witz bei der pipline die das unternehmen aufweist.
      grüße t.1
      Avatar
      schrieb am 24.10.01 15:18:40
      Beitrag Nr. 27 ()
      www.stockhouse.com/news/news.asp?newsid=947199&tick=ASTM
      aktuelle resultate zur finanzsituation von aastrom.
      grüße t.1


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      Ihr wollt die neue Rakete?? Hier ist sie....